| Literature DB >> 27004520 |
Thomas R Vetter1, Joydip Barman2, Arthur M Boudreaux2, Keith A Jones2.
Abstract
BACKGROUND: Persistently variable success has been experienced in locally translating even well-grounded national clinical practice guidelines, including in the perioperative setting. We have sought greater applicability and acceptance of clinical practice guidelines and protocols with our novel Perioperative Risk Optimization and Management Planning Tool (PROMPT™). This study was undertaken to survey our institutional perioperative clinicians regarding (a) their qualitative recommendations for (b) their quantitative perceptions of the relative importance of a series of clinical issues and patient medical conditions as potential topics for creating a PROMPT™.Entities:
Keywords: Clinical care pathways; Healthcare outcomes; Patient-centered care; Perioperative care; Surgical home
Mesh:
Year: 2016 PMID: 27004520 PMCID: PMC4804473 DOI: 10.1186/s12871-016-0187-0
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1Iterative series of Plan-Do-Study-Act (PDSA) cycles applied to develop, implement, and revise a Perioperative Risk Optimization and Management Planning Tool (PROMPT™)
Fig. 2Prototypic Perioperative Risk Optimization and Management Planning Tool (PROMPT™) for the management of postoperative nausea and vomiting
Fig. 3Perioperative Personalized Care Matrix comprised of both elements of an Integrated Care Pathway (ICP) and any applicable Perioperative Risk Optimization and Management Planning Tool (PROMPT™) [5]
Study participant demographics
| All Participants | Anesthesiologist | CRNA | Anesthesia Care Providers | Surgeons | Anesthesia Care Providers versus Surgeons | ||
|---|---|---|---|---|---|---|---|
| Standardized Difference Score |
| ||||||
| Age, mean ± SD | 47.1 ± 9.8 | 45.6 ± 9.0 | 44.8 ± 10.6 | 45.4 ± 9.4 | 49.3 ± 10.0 | 0.40 | 0.086 |
| Gender, N (%) | 0.24 | 0.459 | |||||
| Female | 17 (21) | 5 | 6 | 11 (23) | 6 (17) | ||
| Male | 64 (77) | 26 | 9 | 35 (73) | 29 (83) | ||
| No response | 2 (2) | 2 | 0 | 2 (4) | 0 | ||
| Experience, mean ± SD | 14.3 ± 9.4 | 13.8 ± 9.3 | 12.5 ± 9.4 | 13.4 ± 9.2 | 15.5 ± 9.7 | 0.22 | 0.332 |
| Race, N, (%) | 0.21 | 0.466 | |||||
| Caucasian | 67 (81) | 27 | 13 | 40 (83) | 27 (77) | ||
| African American | 3 (4) | 1 | 1 | 2 (4) | 1 (3) | ||
| Hispanic | 4 (5) | 1 | 0 | 1 (2) | 3 (9) | ||
| Other | 7 (8) | 2 | 1 | 3 (6) | 4 (11) | ||
| No response | 2 (2) | 2 | 0 | 2 (4) | 0 | ||
CRNA certified registered nurse anesthetist
Perioperative Risk Optimization and Management Planning Tool (PROMPT™) qualitative survey results
| A. Preoperative Testing | |
| 1. Laboratory (11) | |
| 2. Cardiovascular (10) | |
| 3. Pulmonary function (2) | |
| B. Medications and Technologies | |
| 1. Beta-blockers | |
| 2. Calcium channel blockers | |
| 3. Diuretics | |
| 4. Angiotensin-converting enzyme inhibitors | |
| 5. Angiotensin receptor blockers | |
| 6. Anticoagulants (17) | |
| 7. Coronary artery stents (6) | |
| 8. Cardiac pacemakers (4) | |
| 9. Implantable cardioverter defibrillators | |
| 10. Insulin pumps | |
| 11. Intrathecal pumps | |
| 12. Other implantable devices (vagal nerve stimulators, deep brain stimulators) | |
| C. Optimization of Co-Morbid Diseases | |
| 1. Arterial hypertension (25) | |
| 2. Coronary artery disease (3) | |
| 3. Cardiomyopathy | |
| 4. Congestive heart failure (3) | |
| 5. Cardiac arrhythmias (5) | |
| 6. Diabetes mellitus (18) | |
| 7. Cerebrovascular disease (2) | |
| 8. Chronic obstructive pulmonary disease (2) | |
| 9. Obstructive sleep apnea (10) | |
| 10. Pulmonary hypertension | |
| 11. Renal insufficiency (6) | |
| 12. Cirrhosis and liver failure | |
| 13. Anemia (8) | |
| 14. Obesity (7) | |
| 15. Infection and sepsis (11) | |
| 16. Trauma (3) | |
| 17. Chronic pain/chronic opioid use (15) | |
| 18. Substance abuse (3) | |
| 19. Malignant hyperthermia | |
| 20. Reported penicillin allergy | |
| D. Perioperative Risk Reduction | |
| 1. Cognitive delirium (7) | |
| 2. Cognitive dysfunction (4) | |
| 3. Nausea and vomiting (21) | |
| 4. Deep venous thrombosis (8) | |
| 5. Cerebrovascular accident | |
| 6. Myocardial injury after non-cardiac surgery (“MINS”) | |
| 7. Acute kidney injury and renal failure (2) | |
| E. Provision of Comprehensive Care | |
| 1. Choice of anesthetic technique and agents (11) | |
| 2. Airway management (4) | |
| 3. Ventilation (12) | |
| 4. Glucose management (not just in diabetics) (9) | |
| 5. Nutrition (2) | |
| 6. Fluid and Electrolyte Management (16) | |
| 7. Patient-centered blood management (11) | |
| 8. Patient medication instruction and compliance (5) | |
| 9. Preoperative physical conditioning (“prehabilitation”) (2) | |
| 10. Smoking cessation (3) | |
| 11. Perioperative opioid sparring strategies (“multimodal analgesia”) (13) | |
| 12. Perioperative sedative sparring strategies | |
| 13. Preoperative antimicrobial prophylaxis and skin preparation | |
| 14. Intraoperative hypothermia prevention (maintaining normothermia) | |
| 15. Geriatric anesthetic and analgesic management (3) |
Note: Patient medical conditions or clinical issues identified by the survey participants were categorized in to five main sections (A through E above). Survey response counts are shows for each topic (if count > 1)
Specific clinical issues and patient medical conditions sorted by descending order based on all participants’ mean importance score (0 = “Not At All Important,” 10 = “Extremely Important”)
| Clinical Issue/Patient Medical Condition | All Participants | Anesthesia Care Providers | Surgeons |
|---|---|---|---|
| ( | ( | ( | |
| Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | |
| Coronary artery stents | 9.2 (9.0, 9.4) | 9.2 (9.0, 9.5) | 9.2 (8.9, 9.6) |
| Airway management | 9.1 (8.8, 9.5) | 8.9 (8.4, 9.5) | 9.4 (9.0, 9.8) |
| Myocardial infarction or injury after non-cardiac surgery | 9.1 (8.8, 9.4) | 9.2 (8.9, 9.5) | 8.9 (8.4, 9.4) |
| Malignant hyperthermia | 9.1 (8.7, 9.5) | 9.2 (8.7, 9.7) | 8.8 (8.1, 9.5) |
| Ventilation | 9.1 (8.8, 9.4) | 9.0 (8.5, 9.5) | 9.2 (8.8, 9.6) |
| Implantable cardioverter defibrillators | 8.9 (8.7, 9.2) | 9.0 (8.7, 9.3) | 8.8 (8.4, 9.2) |
| Pulmonary hypertension | 8.9 (8.6, 9.2) | 9.1 (8.8, 9.4) | 8.5 (8.0, 9.0) |
| Congestive heart failure | 8.8 (8.6, 9.1) | 9.0 (8.6, 9.3) | 8.6 (8.2, 9.0) |
| Cardiomyopathy | 8.8 (8.5, 9.1) | 8.9 (8.6, 9.3) | 8.6 (8.2, 9.1) |
| Coronary artery disease | 8.7 (8.5, 9.0) | 8.8 (8.5, 9.2) | 8.6 (8.1, 9.0) |
| Anticoagulants | 8.7 (8.3, 9.1) | 8.3 (7.8, 8.8) | 9.3 (8.9, 9.7) |
| Cardiac arrhythmias | 8.6 (8.4, 8.9) | 8.7 (8.3, 9.0) | 8.6 (8.2, 9.0) |
| Preoperative antimicrobial prophylaxis and skin preparation | 8.6 (8.2, 9.0) | 8.4 (7.8, 9.0) | 9.0 (8.6, 9.4) |
| Cardiac pacemakers | 8.6 (8.3, 8.9) | 8.6 (8.2, 9.0) | 8.6 (8.1, 9.1) |
| Acute kidney injury and renal failure | 8.5 (8.2, 8.9) | 8.8 (8.4, 9.2) | 8.2 (7.6, 8.8) |
| Infection and sepsis | 8.5 (8.2, 8.8) | 8.4 (8.0, 8.8) | 8.7 (8.2, 9.1) |
| Intraoperative hypothermia prevention (maintaining normothermia) | 8.4 (8.1, 8.8) | 8.6 (8.2, 9.0) | 8.2 (7.5, 8.9) |
| Cardiovascular testing | 8.3 (8.0, 8.6) | 8.5 (8.1, 8.9) | 8.0 (7.4, 8.5) |
| Cerebrovascular accident | 8.2 (7.9, 8.6) | 8.5 (8.1, 8.9) | 7.8 (7.1, 8.5) |
| Patient medication instruction and compliance | 8.2 (7.9, 8.5) | 8.2 (7.8, 8.6) | 8.1 (7.6, 8.7) |
| Laboratory testing | 8.2 (7.8, 8.5) | 8.3 (7.9, 8.7) | 8.0 (7.4, 8.5) |
| Deep venous thrombosis | 8.1 (7.8, 8.5) | 7.9 (7.4, 8.5) | 8.4 (8.0, 8.9) |
| Cerebrovascular disease | 8.1 (7.8, 8.4) | 8.4 (8.0, 8.7) | 7.8 (7.2, 8.3) |
| Geriatric anesthetic and analgesic management | 8.1 (7.8, 8.4) | 8.2 (7.7, 8.7) | 7.9 (7.5, 8.4) |
| Patient-centered blood management | 8.0 (7.7, 8.4) | 8.3 (7.8, 8.7) | 7.7 (7.2, 8.2) |
| Trauma | 8 .0 (7.6, 8.5) | 8.5 (7.9, 9.0) | 7.3 (6.6, 8.1) |
| Arterial hypertension | 8.0 (7.7, 8.3) | 8.1 (7.6, 8.6) | 7.9 (7.4, 8.3) |
| Cirrhosis and liver failure | 8.0 (7.6, 8.4) | 7.9 (7.4, 8.3) | 8.2 (7.6, 8.8) |
| Perioperative opioid sparing strategies (“multimodal analgesia”) | 7.9 (7.5, 8.3) | 8.2 (7.6, 8.7) | 7.5 (7.0, 8.0) |
| Fluid and electrolyte management | 7.8 (7.4, 8.2) | 7.7 (7.1, 8.2) | 8.0 (7.5, 8.5) |
| Beta-blockers | 7.8 (7.4, 8.2) | 7.6 (7.1, 8.1) | 8.0 (7.4, 8.6) |
| Insulin pumps | 7.8 (7.4, 8.2) | 7.9 (7.4, 8.4) | 7.6 (6.8, 8.4) |
| Obstructive sleep apnea | 7.8 (7.4, 8.1) | 7.8 (7.3, 8.3) | 7.7 (7.3, 8.2) |
| Diabetes mellitus | 7.7 (7.4, 8.1) | 7.9 (7.4, 8.4) | 7.5 (6.9, 8.1) |
| Chronic obstructive pulmonary disease | 7.7 (7.4, 8.1) | 7.7 (7.3, 8.1) | 7.9 (7.3, 8.4) |
| Renal insufficiency | 7.5 (7.1, 7.9) | 7.4 (6.9, 8.0) | 7.6 (6.9, 8.3) |
| Glucose management (not just in diabetics) | 7.5 (7.1, 7.8) | 7.5 (7.0, 8.0) | 7.5 (6.9, 8.0) |
| Nausea and vomiting | 7.4 (7.0, 7.8) | 7.8 (7.3, 8.4) | 6.8 (6.2, 7.4) |
| Choice of anesthetic technique and agents | 7.4 (6.9, 7.9) | 7.3 (6.6, 8.0) | 7.5 (6.8, 8.3) |
| Preoperative physical conditioning (“prehabilitation”) | 7.4 (7.0, 7.8) | 7.6 (7.2, 8.1) | 7.0 (6.3, 7.7) |
| Cognitive delirium | 7.3 (6.8, 7.8) | 7.6 (7.1, 8.2) | 6.8 (6.1, 7.5) |
| Anemia | 7.3 (6.9, 7.7) | 7.3 (6.7, 7.8) | 7.3 (6.8, 7.8) |
| Cognitive dysfunction | 7.3 (6.8, 7.7) | 7.6 (7.0, 8.2) | 6.7 (6.1, 7.3) |
| Perioperative sedative sparing strategies | 7.2 (6.7, 7.7) | 7.5 (6.9, 8.1) | 6.7 (6.1, 7.4) |
| Smoking cessation | 7.0 (6.5, 7.5) | 6.8 (6.1, 7.5) | 7.2 (6.5, 7.9) |
| Chronic pain/chronic opioid use | 6.9 (6.5, 7.3) | 7.2 (6.6, 7.7) | 6.6 (6.1, 7.1) |
| Substance abuse | 6.9 (6.6, 7.3) | 6.9 (6.4, 7.3) | 7.0 (6.4, 7.7) |
| Obesity | 6.9 (6.4, 7.3) | 6.7 (6.1, 7.4) | 7.1 (6.5, 7.7) |
| Other implantable devices (vagal nerve stimulators, deep brain stimulators) | 6.9 (6.4, 7.3) | 7.0 (6.3, 7.7) | 6.7 (6.0, 7.4) |
| Nutrition | 6.8 (6.4, 7.2) | 6.4 (5.9, 7.0) | 7.4 (6.9, 7.9) |
| Angiotensin receptor blockers | 6.8 (6.4, 7.2) | 7.2 (6.7, 7.7) | 6.2 (5.6, 6.8) |
| Angiotensin-converting enzyme inhibitors | 6.8 (6.4, 7.1) | 7.1 (6.6, 7.6) | 6.2 (5.6, 6.8) |
| Reported penicillin allergy | 6.7 (6.2, 7.2) | 6.9 (6.2, 7.5) | 6.4 (5.6, 7.2) |
| Intrathecal pumps | 6.7 (6.2, 7.2) | 6.8 (6.2, 7.4) | 6.6 (5.7, 7.4) |
| Calcium channel blockers | 6.5 (6.2, 6.9) | 6.5 (6.0, 7.1) | 6.6 (6.0, 7.2) |
| Pulmonary function testing | 6.0 (5.4, 6.6) | 5.4 (4.6, 6.3) | 6.8 (6.1, 7.4) |
| Diuretics | 5.8 (5.4, 6.3) | 5.6 (5.0, 6.2) | 6.1 (5.4, 6.8) |
Fig. 4Scatterplot observed between the quantitative clinician survey rating scores reported by the anesthesiologists/certified registered nurse anesthetists versus the surgeons (r = 0.82, 95 % CI: 0.71, 0.89, P < 0.001)
Specific clinical issues and patient medical conditions significantly differently rated by the anesthesia care providers (anesthesiologists/certified registered nurse anesthetists) versus the surgeons (0 = “Not At All Important,” 10 = “Extremely Important”)
| Patient Condition | Anesthesia Care Providers ( | Surgeons ( | Standardized Difference Score |
|
|---|---|---|---|---|
| Mean (95 % CI) | Mean (95 % CI) | |||
| Anticoagulants | 8.3 (7.8, 8.8) | 9.3 (8.9, 9.7) | 0.65 | 0.008 |
| Trauma | 8.5 (7.9, 9.0) | 7.3 (6.6, 8.1) | 0.62 | 0.011 |
| Angiotensin receptor blockers | 7.2 (6.7, 7.7) | 6.2 (5.6, 6.8) | 0.57 | 0.013 |
| Nausea and vomiting | 7.8 (7.3, 8.4) | 6.8 (6.2, 7.4) | 0.57 | 0.019 |
| Nutrition | 6.4 (5.9, 7.0) | 7.4 (6.9, 7.9) | 0.57 | 0.022 |
| Pulmonary function testing | 5.4 (4.6, 6.3) | 6.8 (6.1, 7.4) | 0.56 | 0.018 |
| Angiotensin-converting enzyme inhibitors | 7.1 (6.6, 7.6) | 6.2 (5.6, 6.8) | 0.51 | 0.025 |
| Cognitive dysfunction | 7.6 (7.0, 8.2) | 6.7 (6.1, 7.3) | 0.48 | 0.047 |
| Cognitive delirium | 7.6 (7.1, 8.2) | 6.8 (6.1, 7.5) | 0.40 | 0.094 |